Mobile Virtual Positive Experiences for Anhedonia (MVR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03715400|
Recruitment Status : Suspended (COVID-19 Restrictions for in-person study procedures)
First Posted : October 23, 2018
Last Update Posted : December 11, 2020
|Condition or disease||Intervention/treatment||Phase|
|Anhedonia Virtual Reality Depression Mood Disorders Stress Anxiety||Behavioral: Positive Virtual Reality Training||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||74 participants|
|Intervention Model:||Factorial Assignment|
|Official Title:||Mobile Virtual Positive Experiences for Anhedonia|
|Actual Study Start Date :||September 1, 2018|
|Estimated Primary Completion Date :||January 1, 2021|
|Estimated Study Completion Date :||January 1, 2021|
No Intervention: Control
The control group will not undergo the positive virtual reality training program. Instead, they will complete all self-report and behavioral measures and have the option to experience the positive virtual reality training program upon the conclusion of the study.
Experimental: Positive Virtual Reality Training Intervention
The experimental group will undergo the positive virtual reality training program, which consists of 7 virtual reality (VR) sessions to be completed at home after orientation to the program, in addition to all self-report and behavioral measures.
Behavioral: Positive Virtual Reality Training
Participants will undergo 7 45 minute sessions of positive virtual reality training over the course of four weeks. All assessments will be completed online at home following initial orientation to the program.
Other Name: Mobile Virtual Reality Training
- Change in anhedonia [ Time Frame: Baseline to Post-treatment (4 weeks) ]Change in anhedonia as measured by the anhedonia subscale of the Mood and Anxiety Symptom Questionnaire (MASQ) (max: 110, min: 22, with a higher score indicating higher anhedonia)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03715400
|United States, California|
|University of California, Los Angeles|
|Los Angeles, California, United States, 90095|
|Principal Investigator:||Michelle Craske, PhD||University of California, Los Angeles|